Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia

BACKGROUND: Hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitors have been recently developed to inhibit NS5A activities and have been approved for the treatment of HCV infection. However the drawback of these direct acting antivirals (DAAs) is the emergence of resistance mutations. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Aissa Larousse, Jameleddine, Trimoulet, Pascale, Recordon Pinson, Patricia, Tauzin, Brigitte, Azzouz, Mohamed Mssadak, Ben Mami, Nabyl, Cheikh, Imed, Triki, Henda, Fleury, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465297/
https://www.ncbi.nlm.nih.gov/pubmed/26047611
http://dx.doi.org/10.1186/s12985-015-0318-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465297/
https://www.ncbi.nlm.nih.gov/pubmed/26047611
http://dx.doi.org/10.1186/s12985-015-0318-0

Ejemplares similares